Insider Selling: Dermira Inc (DERM) Insider Sells $82,020.00 in Stock

Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $27.34, for a total transaction of $82,020.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Dermira Inc (NASDAQ:DERM) traded down $0.88 during trading hours on Friday, reaching $28.01. 352,050 shares of the company’s stock traded hands, compared to its average volume of 547,903. Dermira Inc has a 12 month low of $21.35 and a 12 month high of $38.75. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40.

Several research firms recently commented on DERM. BidaskClub upgraded shares of Dermira from a “hold” rating to a “buy” rating in a research note on Wednesday. Guggenheim reiterated a “buy” rating and set a $30.00 price objective on shares of Dermira in a research note on Thursday, December 14th. Mizuho reduced their price objective on shares of Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. Cantor Fitzgerald set a $45.00 target price on shares of Dermira and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Finally, Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Four equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Dermira currently has an average rating of “Hold” and an average price target of $41.00.

A number of large investors have recently added to or reduced their stakes in DERM. Point72 Asset Management L.P. grew its position in Dermira by 621.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock worth $19,248,000 after purchasing an additional 614,138 shares during the last quarter. BlackRock Inc. grew its position in Dermira by 15.6% during the 2nd quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock worth $114,294,000 after purchasing an additional 529,405 shares during the last quarter. Voya Investment Management LLC grew its position in Dermira by 61.4% during the 2nd quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock worth $35,783,000 after purchasing an additional 467,356 shares during the last quarter. Jennison Associates LLC grew its position in Dermira by 16.7% during the 2nd quarter. Jennison Associates LLC now owns 2,632,994 shares of the biopharmaceutical company’s stock worth $76,725,000 after purchasing an additional 377,554 shares during the last quarter. Finally, State Street Corp grew its position in Dermira by 38.4% during the 2nd quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock worth $23,946,000 after purchasing an additional 228,093 shares during the last quarter. 99.47% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/23/insider-selling-dermira-inc-derm-insider-sells-82020-00-in-stock.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

What are top analysts saying about Dermira? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dermira and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit